Discover
ENTA
Enanta Pharmaceuticals, Inc.
14.77
2 x 10.73
2 x 18.90
bid
ask
+
0.19
1.30%
2 @ 04:00 PM
14.77 +0.00 (0.00%)
| Ytd | -6.34% | |
| 1y | 91.82% |
14.63
day range
15.20
6.43
52 week range
17.15
| Open | 14.63 | Prev Close | 14.58 | Low | 14.63 | High | 15.20 | Mkt Cap | 429.49M |
| Vol | 198.52K | Avg Vol | 199.32K | EPS | -2.60 | P/E | N/A | Forward P/E | -1.32 |
| Beta | 0.57 | Short Ratio | 20.91 | Inst. Own | 100.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 13.36 | 200-d Avg | 12.91 | 1yr Est | 16.88 |
| Income Statement | |||
| Total Revenue | 17.16M | ||
| Revenues (USD) | 17.16M | ||
| Gross Profit | 17.16M | ||
| Operating Expenses | 29.01M | ||
| Research and Development Expense | 19.44M | ||
| Selling, General and Administrative Expense | 9.57M | ||
| Operating Income | -11.85M | ||
| Interest Expense | 3.32M | ||
| Income Tax Expense | 7.00K | ||
| Net Income | -13.09M | ||
| Net Income Common Stock | -13.09M | ||
| Net Income Common Stock (USD) | -13.09M | ||
| Consolidated Income | -13.09M | ||
| Earnings per Basic Share | -0.45 | ||
| Earnings per Basic Share (USD) | -0.45 | ||
| Earnings per Diluted Share | -0.45 | ||
| Earning Before Interest & Taxes (EBIT) | -9.77M | ||
| Earning Before Interest & Taxes (USD) | -9.77M | ||
| Weighted Average Shares | 29.04M | ||
| Weighted Average Shares Diluted | 29.04M | ||
| Balance Sheet | |||
| Cash and Equivalents | 34.93M | ||
| Cash and Equivalents (USD) | 34.93M | ||
| Investments | 195.44M | ||
| Investments Current | 128.85M | ||
| Investments Non-Current | 66.60M | ||
| Trade and Non-Trade Receivables | 7.81M | ||
| Current Assets | 178.41M | ||
| Property, Plant & Equipment Net | 69.55M | ||
| Total Assets | 314.70M | ||
| Debt Current | 3.76M | ||
| Total Debt | 56.54M | ||
| Current Liabilities | 46.44M | ||
| Debt Non-Current | 52.78M | ||
| Total Liabilities | 198.12M | ||
| Accumulated Retained Earnings (Deficit) | -429.96M | ||
| Accumulated Other Comprehensive Income | -734.00K | ||
| Shareholders Equity | 116.59M | ||
| Shareholders Equity (USD) | 116.59M | ||
| Assets Non-Current | 136.29M | ||
| Total Debt (USD) | 56.54M | ||
| Deferred Revenue | 128.77M | ||
| Liabilities Non-Current | 151.68M | ||
| Trade and Non-Trade Payables | 4.36M | ||
| Tax Assets | 19.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.21M | ||
| Net Cash Flow from Financing | -7.29M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -2.51M | ||
| Capital Expenditure | -15.00K | ||
| Issuance (Purchase) of Equity Shares | 49.00K | ||
| Issuance (Repayment) of Debt Securities | -7.04M | ||
| Net Cash Flow from Investing | 11.94M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 11.96M | ||
| Net Cash Flow from Operations | -7.16M | ||
| Share Based Compensation | 3.75M | ||